[go: up one dir, main page]

Heeringa et al., 1998 - Google Patents

Expression of iNOS, eNOS, and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis

Heeringa et al., 1998

View PDF
Document ID
7816691642252602651
Author
Heeringa P
van Goor H
Moshage H
Klok P
Huitema M
de Jager A
Schep A
Kallenberg C
Publication year
Publication venue
Kidney international

External Links

Snippet

Expression of iNOS, eNOS and peroxynitrite-modified proteins in experimental anti-MPO associated necrotizing crescentic glomerulonephritis. Nitric oxide radicals are recognized as important mediators in various physiological and pathophysiological processes. During …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Heeringa et al. Expression of iNOS, eNOS, and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis
Bakker et al. Blood-brain barrier permeability during Cuprizone-induced demyelination: Implications for the pathogenesis of immune-mediated demyelinating diseases
Seya et al. Quanatitative analysis of membrane cofactor protein (MCP) of complement: High expression of MCP on human leukemia cell lines, which is down-regulated during cell-differentiation
Passwell et al. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis.
Poelstra et al. Intraglomerular platelet aggregation and experimental glomerulonephritis
ES2632625T3 (en) Composition for use in the treatment of a disease
Matsuo et al. Glomerulonephritis induced in the rabbit by antiendothelial antibodies.
Jansen et al. In situ complement activation in porcine membranoproliferative glomerulonephritis type II
US20030086929A1 (en) Treatment of prostate cancer by inhibitors of ATP synthase
US20070065433A1 (en) Methods and compositions for the treatment of meconium aspiration syndrome
US6153195A (en) Method of delivering drugs to cells specific for an HL-60 lectin
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
DE69331100T2 (en) USE OF P97 IN DIAGNOSIS OF MORBUS ALZHEIMER
DE69431167T2 (en) METHOD FOR SELECTIVE METHIONINE DRAWNING FOR MALIGNE MAMMAL CELLS
Miyamoto et al. Immunohistochemical study of the membrane attack complex of complement in IgA nephropathy
WO2005117848A9 (en) Vascular targets for detecting, imaging and treating neoplasia or neovasculature
Scherberich et al. Glomerular and tubular membrane antigens reflecting cellular adaptation in human renal failure.
CA2758829C (en) Method of treating demyelinating disease
van Kleef et al. In vitro and in vivo expression of endothelial von Willebrand factor and leukocyte accumulation after fractionated irradiation
Quigg et al. Studies with antibodies to cultured rat glomerular epithelial cells. Subepithelial immune deposit formation after in vivo injection
Redline et al. Defective anti-listerial responses in deciduoma of pseudopregnant mice
Van Dixhoorn et al. Characterization of complement C6 deficiency in a PVG/c rat strain
WO1999049865A1 (en) Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
Davin et al. Urinary excretion of neutral proteinases in nephrotic rats with a glomerular disease
Bazin et al. The metabolism of different immunoglobulin classes in irradiated mice: V. Contribution of the gut to serum IgA levels in normal and irradiated mice